TScan Therapeutics (TCRX) Operating Income Growth (3y) (2023 - 2026)

TScan Therapeutics (TCRX) Operating Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Oculis Holding AG 66,801.52 Bn 66,801.23 Bn - 16.96%
2 Nanobiotix 1,916.61 Bn 1,916.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.65 Bn 466.85 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 121.94 Bn 114.69 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 69.85 Bn 61.09 Bn 3.31 Bn -12.10%
7 Belite Bio 63.06 Bn 63.06 Bn - -
8 Argenx Se 55.74 Bn 50.56 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.48 Bn 37.48 Bn - -
10 TScan Therapeutics 100.19 Mn -27.87 Mn - -8.61%

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.61%
Dec 31, 2025 -8.56%
Sep 30, 2025 -30.75%
Jun 30, 2025 -36.36%
Mar 31, 2025 -30.90%
Dec 31, 2024 -37.24%
Sep 30, 2024 -27.22%
Jun 30, 2024 -47.28%
Mar 31, 2024 -58.24%
Dec 31, 2023 -39.84%
Sep 30, 2023 -51.12%
Jun 30, 2023 -63.64%